Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.
Term
16 weeks
“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
Corbus Pharmaceuticals reported a net loss of $95.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses related to its ADC and obesity pipelines. The company's cash and investment position decreased to approximately $115.3 million from $163.3 million at the end of 2025, despite raising $27.6 million through common stock issuances.
Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.
“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
Cormorant Asset Management LP sold 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. at $4.10 a share, worth $1.74M in total on Oct 29, 2026. Shares held after the trade: 1,919,971 (-18.1%).
Corbus Pharmaceuticals updated its corporate investor presentation to highlight its clinical pipeline in oncology and obesity. Key focus areas include the CRB-701 Nectin-4 ADC, which is entering a registrational Phase 2 study for OPSCC, and CRB-913, a CB1 inverse agonist for obesity with a Phase 2 study expected to start in the first half of 2027.